PV Bulletin

Exemptions Granted to Small Business Dispensers Under the Drug Supply Chain Security Act

FDA has announced exemptions for small business dispensers from certain regulatory requirements until November 27, 2027.

PV Impact Brief

MonitoringConfidence: high

What changed

Exemptions from certain requirements under section 582 of the FD&C Act granted to small business dispensers until November 27, 2027.

Why it matters

These exemptions alleviate the regulatory burden on small dispensers, ensuring patient access to medications while allowing additional time for compliance assessments.

Action needed

Small business dispensers are encouraged to complete a mandatory assessment survey by September 22, 2026, and do not need to submit information to the FDA while utilizing these exemptions.

Relevant for
Regulatory Intelligence Lead
Processes impacted
Country Compliance
Owner

Regulatory Intelligence Lead

Review cadence

Review in the next regulatory intelligence cycle.

Evidence and confidence

Confidence: highSource updated: Aug 26, 2026

Full briefing

Practical implication

Small business dispensers are encouraged to complete a mandatory assessment survey by September 22, 2026, and do not need to submit information to the FDA while utilizing these exemptions.

The FDA has issued exemptions from specific requirements of section 582 of the FD&C Act for small business dispensers, valid until November 27, 2027. This change allows time for these dispensers to complete an assessment and facilitates compliance adaptations for those with 25 or fewer full-time employees.

What changed: Exemptions from certain requirements under section 582 of the FD&C Act granted to small business dispensers until November 27, 2027.

Why it matters: These exemptions alleviate the regulatory burden on small dispensers, ensuring patient access to medications while allowing additional time for compliance assessments.

Practical implication: Small business dispensers are encouraged to complete a mandatory assessment survey by September 22, 2026, and do not need to submit information to the FDA while utilizing these exemptions.

View original source

  • Source: FDA - What's New Drugs RSS
  • Published at source: 2026-08-26T00:00:00.000Z
  • Discovered by monitor: 2026-08-26T22:31:10.387Z

Published from the regulator source ingestion pipeline after PV impact triage.

Related updates for your role

publicFDA · USA · Updated Sep 4, 2026

FDA Grants Accelerated Approval to Etcamah for Advanced Breast Cancer

Urgency: High

Regulatory teams must prepare for updating labeling to include details on the new indication and required diagnostic methods, along with planning for the confirmatory studies mandated by the FDA.

Signal ManagementLabelingRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicMHRA · UK · Updated Sep 4, 2026

Change to the definition of regulated activity with children from 1 September 2026

Urgency: High

Organizations must re-evaluate roles related to children's activities and prepare to request Enhanced DBS checks including access to the Children’s Barred List check starting from 1 September 2026.

Country ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicANSM (France) · France · Updated Sep 7, 2026Translated From French

Urgent Withdrawal of Reusable da Vinci S and Si Instruments Due to Cable Degradation

Urgency: High

Healthcare facilities must isolate the affected instruments and notify Intuitive Surgical for returns while preparing for potential delays in surgical procedures due to instrument replacements.

Signal ManagementRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Latest
Read impact briefarrow_forward
publicANSM · France · Updated Sep 7, 2026Translated From French

Injunction No. 2026-DM-031-INJ Regarding Ortho Partner Establishment in Montreuil

Urgency: High

Establish compliant storage conditions for medical devices and set up a non-conformity management system within 3 months.

Inspection ReadinessRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward